BRPI0406776A - Composição farmacêutica, método de avaliação fisiológica e uso de pelo menos um dentre um inibidor de uma molécula semelhante a resistina (alfa) (relm(alfa)), uma molécula semelhante a resistina ß (relmß), um regulador de expressão de relm(alfa) ou um regulador de expressão de relmß - Google Patents

Composição farmacêutica, método de avaliação fisiológica e uso de pelo menos um dentre um inibidor de uma molécula semelhante a resistina (alfa) (relm(alfa)), uma molécula semelhante a resistina ß (relmß), um regulador de expressão de relm(alfa) ou um regulador de expressão de relmß

Info

Publication number
BRPI0406776A
BRPI0406776A BR0406776-2A BRPI0406776A BRPI0406776A BR PI0406776 A BRPI0406776 A BR PI0406776A BR PI0406776 A BRPI0406776 A BR PI0406776A BR PI0406776 A BRPI0406776 A BR PI0406776A
Authority
BR
Brazil
Prior art keywords
relm
alpha
resistin
regulator
expression
Prior art date
Application number
BR0406776-2A
Other languages
English (en)
Inventor
Marc Elliot Rothenberg
Original Assignee
Childrens Hosp Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hosp Medical Center filed Critical Childrens Hosp Medical Center
Publication of BRPI0406776A publication Critical patent/BRPI0406776A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Pathology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA, MéTODO DE AVALIAçãO FISIOLóGICA E USO DE PELO MENOS UM DENTRE UM INIBIDOR DE UMA MOLéCULA SEMELHANTE A RESISTINA A (RELM<244>), uma molécula semelhante a RESISTINA <225> (RELM<225>), UM REGULADOR DE EXPRESSãO DE RELMA OU UM REGULADOR DE EXPRESSãO DE RELM<225>". Composição e método para alívio de uma resposta alérgica por regulação da expressão de moléculas <244> ou <225> semelhantes a resistina (RELM<244> ou RELM<225>). As RELMs são também reveladas como marcadores para avaliação do estado alérgico do paciente, por exemplo, monitorando a inflamação e/ou a restauração tecidular no pulmão ou nas vias aéreas do paciente asmático. A regulação das RELMs está envolvida na patogênese da inflamação alérgica pulmonar e outras condições induzidas por alérgenos. A constatação do envolvimento da RELM<244> e RELM<225> na asma liga, do ponto de vista de mecanismos, a patogênese da resistência à insulina e obesidade, conhecidas como envolvendo RELMs, à asma.
BR0406776-2A 2003-01-18 2004-01-16 Composição farmacêutica, método de avaliação fisiológica e uso de pelo menos um dentre um inibidor de uma molécula semelhante a resistina (alfa) (relm(alfa)), uma molécula semelhante a resistina ß (relmß), um regulador de expressão de relm(alfa) ou um regulador de expressão de relmß BRPI0406776A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44092203P 2003-01-18 2003-01-18
PCT/US2004/001139 WO2004067026A1 (en) 2003-01-18 2004-01-16 Regulation of allergen induced gene

Publications (1)

Publication Number Publication Date
BRPI0406776A true BRPI0406776A (pt) 2005-12-27

Family

ID=32825146

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0406776-2A BRPI0406776A (pt) 2003-01-18 2004-01-16 Composição farmacêutica, método de avaliação fisiológica e uso de pelo menos um dentre um inibidor de uma molécula semelhante a resistina (alfa) (relm(alfa)), uma molécula semelhante a resistina ß (relmß), um regulador de expressão de relm(alfa) ou um regulador de expressão de relmß

Country Status (7)

Country Link
US (1) US20040198686A1 (pt)
EP (1) EP1594525A1 (pt)
JP (1) JP2006517962A (pt)
AU (1) AU2004207476A1 (pt)
BR (1) BRPI0406776A (pt)
CA (1) CA2512808A1 (pt)
WO (1) WO2004067026A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5229866B2 (ja) * 2007-12-12 2013-07-03 国立大学法人広島大学 大腸癌、動脈硬化症、又はメタボリックシンドロームの検出方法
CA2722668A1 (en) * 2008-04-29 2009-11-05 Wyeth Llc Methods for treating inflammation
EP2858679B2 (en) * 2012-06-08 2024-06-05 Translate Bio, Inc. Pulmonary delivery of mrna to non-lung target cells
US20230003743A1 (en) * 2020-02-24 2023-01-05 The Children's Medical Center Corporation Methods and compositions for treating or preventing an allergy or anaphylaxis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU643427B2 (en) * 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
MX9700764A (es) * 1994-07-29 1997-05-31 Smithkline Beecham Plc Compuestos novedosos.
NZ512942A (en) * 1998-12-14 2004-01-30 Univ Johns Hopkins Polynucleotides encoding the IL-13 binding chains of the interleukin receptor, pharmaceutical compositions comprising the protein and methods of identifying inhibitors
AU2001268232A1 (en) * 2000-06-09 2001-12-24 The Trustees Of The University Of Pennsylvania Compositions, methods, and kits relating to resistin-like molecules
JP2002338537A (ja) * 2001-05-16 2002-11-27 Mitsubishi Pharma Corp アミド化合物およびその医薬用途
AU2003241182A1 (en) * 2002-06-05 2003-12-22 Asahi Kasei Pharma Corporation Stat6 activation gene

Also Published As

Publication number Publication date
US20040198686A1 (en) 2004-10-07
AU2004207476A1 (en) 2004-08-12
EP1594525A1 (en) 2005-11-16
JP2006517962A (ja) 2006-08-03
WO2004067026A1 (en) 2004-08-12
WO2004067026A8 (en) 2004-10-21
CA2512808A1 (en) 2004-08-12

Similar Documents

Publication Publication Date Title
Blanco et al. Mitochondrial DNA variation and the pathogenesis of osteoarthritis phenotypes
Ho-Pham et al. More on body fat cutoff points
Tetik et al. Determination of oxidant stress in plasma of rheumatoid arthritis and primary osteoarthritis patients
BR112012014801A2 (pt) &#34;uso combinado de proteínas cry1ca e cry1fa para controle de resistência a insetos&#34;
BR0316231A (pt) Métodos para determinar o estado de sepsia para prognosticar o começo de sepsia e para diagnosticar a sìndrome de resposta inflamatória sistêmica em um indivìduo e para isolar um biomarcador, perfil biomarcador r kit
BRPI0518884A2 (pt) mÉtodo para medir a resistÊncia ou sensibilidade ao docetaxel
BRPI0710185A8 (pt) anticorpos contra receptor de fator de crescimento i semelhante à insulina e usos dos mesmos
BRPI0720820A8 (pt) Produto alimentício esterilizado, processo para produzir uma composição de amido, e, uso de um produto alimentício
BRPI0406776A (pt) Composição farmacêutica, método de avaliação fisiológica e uso de pelo menos um dentre um inibidor de uma molécula semelhante a resistina (alfa) (relm(alfa)), uma molécula semelhante a resistina ß (relmß), um regulador de expressão de relm(alfa) ou um regulador de expressão de relmß
BRPI0406789A (pt) Composição farmacêutica e métodos de intensificação de expressão do fator-2 do trefoil (tff2), de avaliação fisiológica pulmonar, de tratamento e de intensificação da restauração de tecido inflamado induzido por alérgeno
Jiao et al. The association between the levels of CRP, IL-10, PLA2, Fbg and prognosis in traumatic fracture of lower limb
DE602005010712D1 (de) Insulinpromotor-faktor 1 als target/marker von beta-zellen-störung
Zambrana-Calví et al. Lipid changes and their relationship with vitamin D levels in children under 18 years with type 1 diabetes
Levy et al. Long Term Follow-Up of Sarcopenia and Malnutrition after Hospitalization for COVID-19 in Conventional or Intensive Care Units. Nutrients 2022; 14: 912
Nakayama et al. Evaluation of glycosaminoglycans levels in normal joint fluid of the knee
Nikolic et al. Familial pneumothorax
Radziavicius et al. The influence of Roux-en-Y gastric bypass surgery on inflammatory markers and pulmonary function amelioration
Sahi et al. Oxidative Stress in Relation to Obesity in Gujrati and Non Gujarati Young Girls before and after Maize Diet
BRMU8400931U (pt) Disposição em conjunto de sialogogo mecânico
Ghanayem et al. Study of the heat shock protein 70-1 gene polymorphism and the risk of nephropathy in type II diabetic patients
Güvenç et al. Dynamic thiol-disulphide homeostasis in grade 3-4 gonarthrosis
Tariq et al. Role of IL-4 and Glutathione Peroxidase in Patients with Obstructive Lung Diseases
Gadre et al. C-peptide and its correlation to parameters of insulin resistance and obesity in Type 2 diabetes
Murphy et al. 60 A comparison of HFrEF vs HFpEF’s clinical workload and cost in the first year following hospitalisation and enrollment in a disease management program
Mirdamadi et al. Congenital Heart Disease with Pulmonary Hypertension; Surgery or Medical Treatment?

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]